GenScript Biotech released its 10th annual Environmental, Social and Governance (ESG) report, detailing 2025 performance and disclosing Science Based Targets initiative (SBTi)-validated goals that commit the company to net-zero emissions by 2050.

Governance & Oversight • A board-level Risk Management and ESG Committee directs strategy, while an ESG Working Team drives execution across global operations. • Climate performance has been linked to executive remuneration, and 100% of board members and employees completed anti-corruption training during the year.

Climate & Environment • Combined Scope 1 and Scope 2 greenhouse-gas emissions fell 10% year-on-year to 148,375.21 tCO₂e (market-based), equal to 1.55 tCO₂e per US$10,000 revenue. • Two major production sites now hold ISO 50001 certification; distributed solar capacity rose to 1,320 MWh, and intelligent energy systems delivered 2,156 t steam and 310 MWh in savings. • Near-term SBTi targets call for a 54.6% absolute reduction in Scope 1&2 emissions and a 32.5% cut in key Scope 3 categories by 2033; 83% of suppliers (by emissions) are expected to set science-based targets by 2029.

Resource Efficiency • Municipal water use declined by 14,000 t through cooling-system optimisation; process upgrades saved a further 1,800 t via condensate reuse. • Plastic packaging was cut by 82% through a shift to recyclable paper-based boxes. • Process innovations such as PFAS-free peptide production and continuous perfusion culture reduced chemical use by up to 80% and wastewater volumes by over 50%.

Workforce & Human Capital • Global headcount reached 6,165, with women representing 58.70% of employees and 49.61% of managerial roles; 56.85% of STEM positions are held by women. • All employees completed professional training, averaging 32.57 hours per person, and no work-related fatalities have occurred for three consecutive years. • GenScript earned LinkedIn’s “Global Talent Magnet Employer” recognition for 2025.

Responsible Supply Chain • The company worked with 2,755 suppliers, 100% of targeted partners signed the Supplier Code of Conduct, and 68% of significant suppliers entered corrective-action or capacity-building programmes. • Fifteen high-priority suppliers underwent on-site ESG audits aligned with Pharmaceutical Supply Chain Initiative (PSCI) principles.

Community & Industry Advancement • Employees logged 4,389 volunteer hours through the “GenTeer” programme, supporting health, education and environmental projects. • The Life Science Research Grant Programme awarded 82 grants in 2025, bringing cumulative funding to US$3.10 million. GenScript also backed over 100 teams in the 2025 iGEM synthetic biology competition.

Recognition • External ratings improved, including an “AA” from MSCI ESG, a Silver Medal from EcoVadis, a “Low Risk” ranking from Sustainalytics, inclusion in FTSE4Good and the S&P Global Sustainability Yearbook 2026, and a “B” score from CDP Climate Change.

GenScript plans to maintain momentum by expanding renewable-energy deployment, tightening supplier ESG oversight and advancing diversity, skills development and community engagement as it progresses toward its 2050 net-zero ambition.